Venlafaxine
Effexor (venlafaxine) is a small molecule pharmaceutical. Venlafaxine was first approved as Effexor on 1993-12-28. It is used to treat attention deficit disorder with hyperactivity, autistic disorder, chronic fatigue syndrome, depressive disorder, and obsessive-compulsive disorder amongst others in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter and sodium-dependent noradrenaline transporter.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
Effexor (generic drugs available since 2006-08-03)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Venlafaxine besylate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VENLAFAXINE BESYLATE | Almatica Pharma | N-215429 RX | 2022-06-29 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| effexor | New Drug Application | 2021-12-01 |
| venlafaxine hydrochloride | ANDA | 2023-06-20 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| attention deficit disorder with hyperactivity | EFO_0003888 | D001289 | F90 |
| autistic disorder | EFO_0003758 | D001321 | F84.0 |
| chronic fatigue syndrome | EFO_0004540 | D015673 | G93.31 |
| depressive disorder | EFO_1002014 | D003866 | F32.A |
| obsessive-compulsive disorder | EFO_0004242 | D009771 | F42 |
| pain | EFO_0003843 | D010146 | R52 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
176 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 3 | 8 | 16 | 19 | 3 | 45 |
| Depression | D003863 | F33.9 | 2 | 8 | 10 | 21 | 7 | 44 | |
| Healthy volunteers/patients | — | 14 | — | 1 | 1 | — | 16 | ||
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 2 | 2 | 3 | 2 | 9 |
| Treatment-resistant depressive disorder | D061218 | — | — | 7 | 1 | 1 | 9 | ||
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 3 | 4 | 2 | 1 | 9 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 1 | 1 | 4 | 1 | 7 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | 3 | 2 | 5 |
| Cognitive dysfunction | D060825 | G31.84 | — | — | — | 1 | 2 | 3 | |
| Social phobia | D000072861 | EFO_1001917 | F40.1 | — | — | 1 | 1 | 1 | 3 |
Show 16 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hot flashes | D019584 | — | — | 2 | — | 4 | 6 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 1 | — | 2 | 4 |
| Panic disorder | D016584 | EFO_0004262 | F41.0 | — | — | 3 | — | 1 | 4 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | 1 | — | 1 | 2 |
| Alcohol-related disorders | D019973 | F10 | — | 1 | 1 | — | 1 | 2 | |
| Prostatic neoplasms | D011471 | C61 | — | 1 | 1 | — | — | 2 | |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | — | 1 | — | — | 1 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | F45.9 | — | — | 1 | — | — | 1 | |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | — | 1 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 1 | — | — | 1 | 2 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | 1 | 1 | — | — | — | 1 |
| Post-head injury coma | D020207 | — | 1 | — | — | — | 1 | ||
| Neck pain | D019547 | HP_0030833 | M54.2 | — | 1 | — | — | — | 1 |
| Cocaine-related disorders | D019970 | F14 | — | 1 | — | — | — | 1 | |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | 1 | 2 |
| Bariatric surgery | D050110 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | — | — | 1 | 1 | ||
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | — | — | — | — | 1 | 1 | ||
| Wounds and injuries | D014947 | T14.8 | — | — | — | — | 1 | 1 | |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | — | 1 | 1 |
| Chronic disease | D002908 | — | — | — | — | 1 | 1 | ||
| Brain injuries | D001930 | S06.9 | — | — | — | — | 1 | 1 | |
| Suicidal ideation | D059020 | EFO_0004320 | R45.851 | — | — | — | — | 1 | 1 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | — | 1 | 1 |
| Squamous cell carcinoma | D002294 | — | — | — | — | 1 | 1 |
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VENLAFAXINE |
| INN | venlafaxine |
| Description | Venlafaxine is a tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group. It has a role as an antidepressant, a serotonin uptake inhibitor, an adrenergic uptake inhibitor, a dopamine uptake inhibitor, an analgesic, an environmental contaminant and a xenobiotic. It is a member of cyclohexanols, a tertiary alcohol, a tertiary amino compound and a monomethoxybenzene. |
| Classification | Small molecule |
| Drug class | antianxiety, antidepressant inhibitor of norepinephrine and dopamine re-uptake |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1 |
Target
Agency Approved
SLC6A4
SLC6A4
SLC6A2
SLC6A2
Organism
Homo sapiens
Gene name
SLC6A4
Gene synonyms
HTT, SERT
NCBI Gene ID
Protein name
sodium-dependent serotonin transporter
Protein synonyms
5-hydroxytryptamine (serotonin) transporter, 5HT transporter, 5HTT, Na+/Cl- dependent serotonin transporter, serotonin transporter 1, solute carrier family 6 (neurotransmitter transporter), member 4, solute carrier family 6 (neurotransmitter transporter, serotonin), member 4, Solute carrier family 6 member 4
Uniprot ID
Mouse ortholog
Slc6a4 (15567)
sodium-dependent serotonin transporter (Q60857)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Effexor - Viatris
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Effexor - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 14,661 documents
View more details
Safety
Black-box Warning
Black-box warning for: Effexor , Venlafaxine hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,735 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more